What is PBM's relative strength rating?

PBM ranks at the 95th percentile over 1 month, 39th percentile over 3 months, 95th percentile over 6 months, 7th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.

What sector is PBM in?

PBM is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.

Is PBM in a leading sector?

Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). PBM benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.

PBM currently shows a 20-day average daily range (ADR%) of 10.2%, a 90-day beta versus the S&P 500 of 1.93. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.

Does PBM have a seasonal pattern?

TickerStance computes PBM's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what PBM has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.

When did PBM last report earnings?

No SEC EDGAR filings are linked to PBM in the current TickerStance fundamentals database. This can occur for tickers without a matched CIK (some ADRs, ETFs, and recently listed securities) or when the fundamentals pipeline has not yet processed this ticker.

Psyence Biomedical Ltd. Common Shares (PBM)

TODAY'S READ · AS OF 2026-08-25

As of 2026-08-25, Psyence Biomedical Ltd. Common Shares (PBM) has a 3-month relative strength percentile of 39 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 44. The current market Stance is 52.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 10.2%, relative volume 0.37×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.

RS methodology →

Market-wide RS; lit = leaderboard

Lenses lit

3 month39pctile

6 month95pctile

1 year7pctile

Classic24IBD pctile

LDR28leadership

0 of 5 lenses lit · avg RS pctile 38

✓ADR%10.2%✓A/DA!RVOL0.37×!$ Vol$301K

Market backdrop

52.9Neutral

Trend30% weight47.0 Breadth30% weight56.3 Leadership20% weight42.0 Macro20% weight60.3 Full stance breakdown →

§ Seasonality

10y · since 2024

Best monthApr on averageavg +40.95% · 33% win · n 3

Worst monthDec on averageavg -44.97% · 0% win · n 2

PBM monthly seasonality strip
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
1	PBM Jan avg: -21.61% median: -24.25% win: 0% σ: 5.78% n: 3 2024-01-29 → 2026-07-31	PBM Feb avg: -42.23% median: -36.56% win: 0% σ: 24.54% n: 3 2024-01-29 → 2026-07-31	PBM Mar avg: 17.50% median: -3.15% win: 33% σ: 81.43% n: 3 2024-01-29 → 2026-07-31	PBM Apr avg: 40.95% median: -21.11% win: 33% σ: 109.94% n: 3 2024-01-29 → 2026-07-31	PBM May avg: -6.22% median: -16.61% win: 33% σ: 37.11% n: 3 2024-01-29 → 2026-07-31	PBM Jun avg: -25.90% median: -26.27% win: 33% σ: 34.28% n: 3 2024-01-29 → 2026-07-31	PBM Jul avg: 31.54% median: 3.60% win: 67% σ: 56.59% n: 3 2024-01-29 → 2026-07-31	PBM Aug avg: -37.34% median: -37.34% win: 0% σ: 9.61% n: 2 2024-01-29 → 2026-07-31 (current)	PBM Sep avg: -30.86% median: -30.86% win: 50% σ: 63.27% n: 2 2024-01-29 → 2026-07-31	PBM Oct avg: -16.03% median: -16.03% win: 0% σ: 20.90% n: 2 2024-01-29 → 2026-07-31	PBM Nov avg: -42.38% median: -42.38% win: 0% σ: 12.79% n: 2 2024-01-29 → 2026-07-31	PBM Dec avg: -44.97% median: -44.97% win: 0% σ: 8.42% n: 2 2024-01-29 → 2026-07-31

Evidence · 1 of 3

Receipts behind the read

2 of 5 pass

Leadership

Is it leading?

Relative strength across horizons plus the leadership score.

1m

95

3m

39

6m

95

1y

7

LDR

—

StageWeinstein stage analysis

Stage 1 · Basing

Smart money

Who's accumulating?

Accumulation rating, relative volume, U/D ratio, breakout-day proof.

A/D ratingaccumulation / distribution

AAccum

RVOL todayvs 50d avg

0.37×

U/D ratiolast 50 sessions

2.67

Breakout volbreakout day vs 50d avg

-50%

50d avg $ volumeliquidity proxy

$301K

Risk profile

How much does it move?

Daily range, ATR, beta, and the math for a 1-ADR stop.

ADR% (20d)avg daily range

10.2%Elevated

ATR(14)14-day EMA

$0.36

ATR%ATR as % of close

8.44%

Beta vs SPY90d rolling

1.93

1-ADR stoprisk from close $4.27

$3.83−10.2%

Fundamentals · PBM

Does the business back the chart?

No SEC filings on file for this ticker. Fundamentals section requires EDGAR coverage.

Evidence · 2 of 3

Sector context

Healthcare · 82th pctile in sector

Top peers · Healthcare

Who else is leading?

ELOX
99RS 3m
FBRX
99RS 3m
MRNA
99RS 3m
PBM
39RS 3m · you

Sector vs market

Healthcare · 3 of 11

Energy100

Technology91

Healthcare82

Financials73

Materials64

Industrials55

Real Estate45

Consumer Staples36

RS pctileLagLead

PEERS · Pharmaceutical Products

Same industry, closest relative strength

4 peers · by RS6M

CRNXCrinetics Pharmaceuticals, Inc.95 TNGXTango Therapeutics, Inc.95 MNPRMonopar Therapeutics Inc. Common Stock95 HELPCybin Inc. Common Stock95

Public attention · PBM

Is the crowd watching?

29/ 100 · vs its own 90-day norm▼ 10 vs 7dOverlooked

Weak relative strength and quiet attention. Little to read here either way.

Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.

News

Company snapshot

SectorHealthcare

IndustryPharmaceutical Products

SIC2834

Float2.5Mshares

Shares out3.8Mshares

Market cap$16.3MNano Cap

FAQ

Frequently asked questions

What is PBM's relative strength rating?: PBM ranks at the 95th percentile over 1 month, 39th percentile over 3 months, 95th percentile over 6 months, 7th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.
What sector is PBM in?: PBM is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.
Is PBM in a leading sector?: Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). PBM benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.
How volatile is PBM?: PBM currently shows a 20-day average daily range (ADR%) of 10.2%, a 90-day beta versus the S&P 500 of 1.93. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.
Does PBM have a seasonal pattern?: TickerStance computes PBM's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what PBM has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.
When did PBM last report earnings?: No SEC EDGAR filings are linked to PBM in the current TickerStance fundamentals database. This can occur for tickers without a matched CIK (some ADRs, ETFs, and recently listed securities) or when the fundamentals pipeline has not yet processed this ticker.

Psyence Biomedical Ltd. Common Shares (PBM) — Stance & relative strength

Lenses lit

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

How much does it move?

Does the business back the chart?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

Is the crowd watching?

Company snapshot

Frequently asked questions

Psyence Biomedical Ltd. Common Shares (PBM) — Stance & relative strength

Lenses lit

Market backdrop

§ Seasonality

Receipts behind the read

Is it leading?

Who's accumulating?

How much does it move?

Does the business back the chart?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

Is the crowd watching?

Company snapshot

Frequently asked questions

§ Seasonality

Psyence Biomedical Ltd. Common Shares (PBM) — Stance & relative strength

PBM is not confirmed as a leader. 39 is not yet a leadership-grade RS read, Market Stance is 52.9

Lenses lit

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

How much does it move?

Does the business back the chart?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

Is the crowd watching?

Company snapshot

Frequently asked questions

Psyence Biomedical Ltd. Common Shares (PBM) — Stance & relative strength

PBM is not confirmed as a leader. 39 is not yet a leadership-grade RS read, Market Stance is 52.9

Lenses lit

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

How much does it move?

Does the business back the chart?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

Is the crowd watching?

Company snapshot

Frequently asked questions